Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Victoria Speed; Lara N. Roberts; Roopen Arya; Jignesh P. Patel

doi:10.1111/jth.15196

Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Victoria Speed^*, Lara N. Roberts, Roopen Arya, Jignesh P. Patel

^*Corresponding author for this work

Institute of Pharmaceutical Science

King's College Hospital

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	872-873
Number of pages	2
Journal	Journal of Thrombosis and Haemostasis
Volume	19
Issue number	3
Early online date	2 Mar 2021
DOIs	https://doi.org/10.1111/jth.15196
Publication status	Published - Mar 2021

Access to Document

10.1111/jth.15196

Cite this

@article{0b7e4c019c3f4722a4233205ec29be9d,

title = "Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment",

author = "Victoria Speed and Roberts, {Lara N.} and Roopen Arya and Patel, {Jignesh P.}",

note = "Funding Information: V. Speed declares no competing interests. Dr. Roberts has received speaker fees and travel grant from Bayer, and investigator‐initiated research grant and travel grant from Sanofi. Dr. Arya reports grants from Bayer; personal fees from Bayer, Pfizer, Medtronic, and Sanofi; and nonfinancial support from Bayer, Pfizer, and Sanofi. Dr. Patel has received an investigator‐initiated research grant from Bayer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

doi = "10.1111/jth.15196",

language = "English",

volume = "19",

pages = "872--873",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Wiley",

number = "3",

}

TY - JOUR

T1 - Fixed dose rivaroxaban can be used in extremes of bodyweight

T2 - A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

AU - Speed, Victoria

AU - Roberts, Lara N.

AU - Arya, Roopen

AU - Patel, Jignesh P.

N1 - Funding Information: V. Speed declares no competing interests. Dr. Roberts has received speaker fees and travel grant from Bayer, and investigator‐initiated research grant and travel grant from Sanofi. Dr. Arya reports grants from Bayer; personal fees from Bayer, Pfizer, Medtronic, and Sanofi; and nonfinancial support from Bayer, Pfizer, and Sanofi. Dr. Patel has received an investigator‐initiated research grant from Bayer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85101814542&partnerID=8YFLogxK

U2 - 10.1111/jth.15196

DO - 10.1111/jth.15196

M3 - Letter

C2 - 33650251

AN - SCOPUS:85101814542

SN - 1538-7933

VL - 19

SP - 872

EP - 873

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 3

ER -

Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Access to Document

Other files and links

Cite this